GKOS Stock Up More Than 45% Since May-End: What's Driving the Rally?
GKOS has surged nearly 45% since May-end as upbeat iDose TR commentary, strong sales and growth expectations lift investor confidence.
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Glaukos is riding strong on iDose TR growth and launching Epioxa into a large underpenetrated market, but reimbursement and competition risks persist.
Glaukos Gains on Q1 Earnings Beat & Improved 2026 Revenue Outlook
GKOS beats Q1 estimates with 41% revenue growth, narrows loss and raises 2026 outlook as glaucoma and corneal segments drive momentum.
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript
Glaukos (GKOS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Glaukos (GKOS) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates
Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.
Glaukos Wins Permanent J-Code for Epioxa Keratoconus Therapy
GKOS secures a permanent CMS J-code for Epioxa, a move set to streamline reimbursement and expand patient access in keratoconus treatment.
Glaukos Launches Epioxa, Boosts Growth in Corneal Treatments
GKOS launches Epioxa, the first FDA-approved topical keratoconus therapy, targeting an underserved market and positioning the company for long-term growth.
Why Is Glaukos (GKOS) Down 14.7% Since Last Earnings Report?
Glaukos (GKOS) reported earnings 30 days ago. What's next for the stock?
Capital International Investors Buys 264,971 Shares of Glaukos Corporation $GKOS
Capital International Investors raised its stake in Glaukos Corporation (NYSE: GKOS) by 107.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 511,510 shares of the medical instruments supplier's stock after acquiring an additional 264,971 shares during the period. Capital International Investors
Glaukos Misses Q4 Earnings Estimates, Raises 2026 Revenue Outlook
GKOS posts 36% Q4 revenue jump, raises 2026 sales outlook to $600-$620M as iDose TR and Epioxa fuel growth despite wider loss.
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
Glaukos Corporation (GKOS) Q4 2025 Earnings Call Transcript
